Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
96.29
+1.64 (1.73%)
Apr 27, 2026, 12:25 PM EDT - Market open
Incyte Employees
Incyte had 2,844 employees as of December 31, 2025. The number of employees increased by 227 or 8.67% compared to the previous year.
Employees
2,844
Change (1Y)
227
Growth (1Y)
8.67%
Revenue / Employee
$1,807,750
Profits / Employee
$452,409
Market Cap
19.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,844 | 227 | 8.67% |
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
| BridgeBio Pharma | 839 |
INCY News
- 6 days ago - Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 18 days ago - Incyte to Report First Quarter Financial Results - Business Wire
- 4 weeks ago - Incyte's skin disease drug shows long-term symptom relief in late-stage trials - Reuters
- 4 weeks ago - Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Business Wire
- 4 weeks ago - Incyte Announces Executive Leadership Appointments - Business Wire
- 5 weeks ago - Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Business Wire
- 5 weeks ago - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico - GlobeNewsWire
- 5 weeks ago - Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil - GlobeNewsWire